ReviewPharmacology & therapeutics2010
Neutralizing endogenous chemokines with small molecules. Principles and potential therapeutic applications.
Review in Pharmacology & therapeutics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Targeting the Angiotensin II Type 1 Receptor in Cerebrovascular Diseases: Biased Signaling Raises New Hopes.International journal of molecular sciences · 2021Review
- Molecular Characteristics and Treatment of Endothelial Dysfunction in Patients with COPD: A Review Article.International journal of molecular sciences · 2019Review
- Chemokines in COPD: From Implication to Therapeutic Use.International journal of molecular sciences · 2019Review
- Breast cancer lung metastasis: Molecular biology and therapeutic implications.Cancer biology & therapy · 2018Review
- CXCL9-Derived Peptides Differentially Inhibit Neutrophil MigrationFrontiers in immunology · 2017Article
- Plasmodium falciparum proteins involved in cytoadherence of infected erythrocytes to chemokine CX3CL1.Scientific reports · 2016Article
- Peptides derived from CXCL8 based on in silico analysis inhibit CXCL8 interactions with its receptor CXCR1.Scientific reports · 2015Article
- Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine.Journal of medicinal chemistry · 2014Article
- Chemokines and chemokine receptors: update on utility and challenges for the clinician.Surgery · 2014Review
- Development of anticancer drugs based on the hallmarks of tumor cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- An antedrug of the CXCL12 neutraligand blocks experimental allergic asthma without systemic effect in mice.The Journal of biological chemistry · 2013Article
- Potential combinatorial effects of recombinant atypical chemokine receptors in breast cancer cell invasion: A research perspective.Biomedical reports · 2013Review
- Prodrugs of a CXC Chemokine-12 (CXCL12) Neutraligand Prevent Inflammatory Reactions in an Asthma Model in Vivo.ACS medicinal chemistry letters · 2012Article
- Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.Current topics in medicinal chemistry · 2012Article
- Glycosaminoglycan analogs as a novel anti-inflammatory strategy.Frontiers in immunology · 2012Article
- Chemokines in health and disease.Experimental cell research · 2011Review
- Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design.Journal of the American Chemical Society · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regulation of cellular responses to external stimuli such as hormones, neurotransmitters, or cytokines is achieved through the control of all steps of the complex cascade starting with synthesis, going through maturation steps, release, distribution, degradation and/or uptake of the signalling molecule interacting with the target protein. One possible way of regulation, referred to as scavenging or neutralization of the ligand, has been increasingly studied, especially for small protein ligands. It shows innovative potential in chemical biology approaches as well as in disease treatment. Neutralization of protein ligands, as for example cytokines or chemokines can lead to the validation of signalling pathways under physiological or pathophysiological conditions, and in certain cases, to the development of therapeutic molecules now used in autoimmune diseases, chronic inflammation and cancer treatment. This review explores the field of ligand neutralization and tries to determine to what extent small chemical molecules could substitute for neutralizing antibodies in therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.